The effect of catheter-directed thrombolytic use on readmission rates and in-hospital outcomes among cancer patients with venous thromboembolism in the United States.

MedStar author(s):
Citation: Journal of Cardiac Surgery. 35(3):609-611, 2020 Mar.PMID: 32017181Institution: MedStar Heart & Vascular Institutena | MedStar Washington Hospital CenterDepartment: Medicine/Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Hospital Mortality | *Mechanical Thrombolysis/ae [Adverse Effects] | *Mechanical Thrombolysis/mt [Methods] | *Neoplasms/co [Complications] | *Patient Readmission/sn [Statistics & Numerical Data] | *Venous Thromboembolism/mo [Mortality] | *Venous Thromboembolism/th [Therapy] | Catheters | Cohort Studies | Costs and Cost Analysis | Female | Humans | Male | Middle Aged | United States/ep [Epidemiology] | Venous Thromboembolism/ec [Economics]Year: 2020ISSN:
  • 0886-0440
Name of journal: Journal of cardiac surgeryAbstract: BACKGROUND: Cancer inducing a hypercoagulable state, venous thromboembolism (VTE) remains a leading cause of morbidity and mortality globally. We assessed the impacts of cancer on the likelihood for readmission after a VTE-targeted procedure.CONCLUSION: The use of CDL does not appear to reduce the risk of returning for a VTE-related admission in cancer. Copyright (c) 2020 Wiley Periodicals, Inc.METHODS: We created a new cohort using discharge-level data from all hospitalizations from State Inpatient Databases of geographically dispersed participating states (18-27 states).RESULTS: In those presenting with VTE during index-admission (619 241), 2.4% patients underwent catheter directed thrombolytic therapy (CDL) on index admission and among those 20.3% had cancer. Moreover, the 30-day readmission rate amongst CDL recipients (10 776 overall) was 14.3% in those with cancer compared to 8.8% in those with no cancer history (P < .0001). Additionally, in-hospital mortality (5.7% vs 1.1%; P = 0.009) and cost-of-care (All authors: Addison D, Barac A, Carter R, Desai NR, Deshmukh AJ, Dey AK, Guha A, McKinley G, Miller PE, Zaghlol ROriginally published: Journal of Cardiac Surgery. 2020 Feb 03Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2020-02-10
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 32017181 Available 32017181

BACKGROUND: Cancer inducing a hypercoagulable state, venous thromboembolism (VTE) remains a leading cause of morbidity and mortality globally. We assessed the impacts of cancer on the likelihood for readmission after a VTE-targeted procedure.

CONCLUSION: The use of CDL does not appear to reduce the risk of returning for a VTE-related admission in cancer. Copyright (c) 2020 Wiley Periodicals, Inc.

METHODS: We created a new cohort using discharge-level data from all hospitalizations from State Inpatient Databases of geographically dispersed participating states (18-27 states).

RESULTS: In those presenting with VTE during index-admission (619 241), 2.4% patients underwent catheter directed thrombolytic therapy (CDL) on index admission and among those 20.3% had cancer. Moreover, the 30-day readmission rate amongst CDL recipients (10 776 overall) was 14.3% in those with cancer compared to 8.8% in those with no cancer history (P < .0001). Additionally, in-hospital mortality (5.7% vs 1.1%; P = 0.009) and cost-of-care ( 1 014 +/- 914 vs 0 520 +/- 534; P = .04) was significantly higher in cancer compared to noncancer.

English

Powered by Koha